Seer to Present at the Cowen 43rd Annual Health Care Conference

REDWOOD CITY, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming Cowen 43rd Annual Health Care Conference in Boston, MA.

Seer’s management is scheduled to participate in a fireside chat and Q&A session on Wednesday, March 8th at 9:50 a.m. Eastern Time / 6:50 a.m. Pacific Time. A live webcast of the session will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be available on the company’s website following the conference.

About Seer Seer™ is a life sciences company developing transformative products that open a new gateway to the proteome. Seer’s Proteograph™ Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.

Investor ContactCarrie Mendivil[email protected]

Media ContactKaren Possemato[email protected]

You May Also Be Interested In

• Pakistan Arrives at LEAP 2026 with Largest-Ever Delegation, Backing “Think Tech, Think Pakistan” with Scale
• Daktronics, Inc. Announces Fiscal 2027 First Quarter Results
• FuelCell Energy Reports Third Fiscal Quarter 2026 Results; Executes First Data Center Power Agreement, Increases Annualized Production Rate & Focuses on Capacity Expansion